| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Department of Radiation Oncology, University Hospital Zürich, CH-8091 Zürich [M. P., C. G., S. B.]; and Friedrich Miescher Institut, CH-4058 Basel [C. W., W. K.], Switzerland
Negative regulation of E2F-1 DNA binding function by cyclin A kinase represents part of an S-phase checkpoint control system that, when activated, leads to apoptosis. In this study, we examined the cellular sensitivity and resistance of isogenic mouse fibrosarcoma cell lines, differing primarily in their p53 status, to ectopic expression of wild-type (wt) E2F-1 and cyclin A kinase binding-defective mutants of it. We found that E2F-1(wt) potently affected the survival of p53+/+ tumor cells but not that of p53-/- cells. In contrast, expression of cyclin A kinase binding-defective E2F-1 species interfered with cell survival of fibrosarcoma cells irrespective of their p53 status. Finally, expression of E2F-1(wt) in p53-/- fibrosarcoma cells enhanced the cytotoxic effect of ionizing radiation in vitro and in vivo in a mouse tumor model. These results suggest that E2F-1-dependent activation of an S-phase checkpoint is p53 independent and that E2F-1 possesses radiosensitizing properties in the absence of p53.
This article has been cited by other articles:
![]() |
T. S. Udayakumar, P. Hachem, M. M. Ahmed, S. Agrawal, and A. Pollack Antisense MDM2 Enhances E2F1-Induced Apoptosis and the Combination Sensitizes Androgen-Dependent and Androgen-Independent Prostate Cancer Cells to Radiation Mol. Cancer Res., November 1, 2008; 6(11): 1742 - 1754. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lee, C. K. Park, J. O. Park, T. Lim, Y. S. Park, H. Y. Lim, I. Lee, T. S. Sohn, J. H. Noh, J. S. Heo, et al. Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy Clin. Cancer Res., January 1, 2008; 14(1): 82 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wang, F. J. Rauscher III, W. D. Cress, and J. Chen Regulation of E2F1 Function by the Nuclear Corepressor KAP1 J. Biol. Chem., October 12, 2007; 282(41): 29902 - 29909. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Hofstetter, V. Vuong, A. Broggini-Tenzer, S. Bodis, I. F. Ciernik, D. Fabbro, M. Wartmann, G. Folkers, and M. Pruschy Patupilone Acts as Radiosensitizing Agent in Multidrug-Resistant Cancer Cells In vitro and In vivo Clin. Cancer Res., February 15, 2005; 11(4): 1588 - 1596. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Jiang, C. B. Matranga, D. Cai, V. M. Latham Jr., X. Zhang, A. M. Lowell, F. Martelli, and G. I. Shapiro Flavopiridol-Induced Apoptosis during S Phase Requires E2F-1 and Inhibition of Cyclin A-Dependent Kinase Activity Cancer Res., November 1, 2003; 63(21): 7410 - 7422. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zaugg, S. Rocha, H. Resch, I. Hegyi, C. Oehler, C. Glanzmann, D. Fabbro, S. Bodis, and M. Pruschy Differential p53-dependent Mechanism of Radiosensitization in Vitro and in Vivo by the Protein Kinase C-specific Inhibitor PKC412 Cancer Res., January 1, 2001; 61(2): 732 - 738. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |